Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 2,274 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ovary Disease Clear all

Conditions: Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions: E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster; Biological · Other
Lead sponsor: COL George Peoples, MD, FACS; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Annandale, Virginia

Conditions: Solid Tumor
Interventions: IMF-001; Biological
Lead sponsor: ImmunoFrontier, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Buffalo, New York • New York, New York

Conditions: Ovarian Cancer, NSCLC, ESCC, Solid Tumors
Interventions: ASP0739; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Duarte, California • Miami, Florida • Chicago, Illinois + 2 more

Conditions: Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
Interventions: gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab; Biological · Drug
Lead sponsor: TCR2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Disorder of Endocrine Ovary, Hypersecretion; Cortisol, Metabolic Disturbance, Stress, Psychological
Interventions: Cognitive behavior therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 74
States / cities: Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Placebo, Lifestyle Intervention; Drug · Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Years to 39 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Ovarian Cancer, Neoadjuvant Chemotherapy, Prehabilitation
Interventions: FIT4SURGERY, Healthy Lifestyle Control; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 60 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ovarian Hyperstimulation Syndrome
Interventions: Human Albumin Infusion, Saline Infusion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 42 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-alcoholic Fatty Liver Disease in Women With PCOS
Interventions: Saroglitazar Magnesium 4 mg Tablet, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 13
States / cities: Chandler, Arizona • Panorama City, California • San Francisco, California + 9 more

Conditions: Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Interventions: mirvetuximab soravtansine (MIRV; IMGN853); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more

Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Acquired Lymphedema, Congenital Lymphedema
Interventions: Perforator Flap Breast Reconstruction, Vascularized Lymph Node Transfer; Procedure
Lead sponsor: The National Institute of Lymphology; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • New Orleans, Louisiana • Charleston, South Carolina

Conditions: Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: XL102, Fulvestrant, Abiraterone, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more

Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
Interventions: VIO-01; Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Lake Mary, Florida • Oklahoma City, Oklahoma • San Antonio, Texas

Conditions: Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 760
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more

Conditions: TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP); Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 20
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more

Conditions: Advanced Solid Tumors, Selected Solid Tumors
Interventions: BKM120 + MEK162; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 5
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Ovarian Carcinoma
Interventions: NanoPac® 100 mg/m2, NanoPac® 200 mg/m2, NanoPac® 300 mg/m2, NanoPac® 400 mg/m2, Standard of Care Intravenous Chemotherapy; Drug
Lead sponsor: NanOlogy, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 4 more

Conditions: Polycystic Ovary Syndrome
Interventions: Estradiol; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cancer
Interventions: graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications; Biological · Genetic · Other + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 8
States / cities: Cleveland, Ohio

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions: auranofin, laboratory biomarker analysis; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Polycystic Ovary Syndrome
Interventions: No intervention; Other
Lead sponsor: David Grant U.S. Air Force Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Travis Air Force Base, California

Conditions: Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Ovarian Cancer
Interventions: VAL-083, Dianhydrogalactitol; Drug
Lead sponsor: DelMar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Detroit, Michigan • Nashville, Tennessee

Search by objective public record fields.

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Pathogenesis of Functional Hypothalamic Amenorrhea

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)

Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The Experience of Living With Polycystic Ovary Syndrome in the Military

Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer